NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Last Close
Apr 21 10:24AM ET
0.8361
Dollar change
-0.0064
Percentage change
-0.76
%
Index- P/E- EPS (ttm)-0.26 Insider Own19.64% Shs Outstand226.60M Perf Week1.35%
Market Cap189.98M Forward P/E- EPS next Y-0.46 Insider Trans0.00% Shs Float182.60M Perf Month-38.07%
Income-56.53M PEG- EPS next Q-0.19 Inst Own58.93% Short Float4.37% Perf Quarter-13.08%
Sales114.70M P/S1.66 EPS this Y-178.50% Inst Trans-7.13% Short Ratio5.26 Perf Half Y-13.80%
Book/sh0.13 P/B6.42 EPS next Y33.93% ROA-18.03% Short Interest7.97M Perf Year1.96%
Cash/sh1.30 P/C0.65 EPS next 5Y14.60% ROE-122.54% 52W Range0.50 - 1.55 Perf YTD-7.57%
Dividend Est.- P/FCF- EPS past 5Y40.29% ROI-24.43% 52W High-46.06% Beta1.87
Dividend TTM- Quick Ratio6.88 Sales past 5Y0.00% Gross Margin96.39% 52W Low67.45% ATR (14)0.10
Dividend Ex-Date- Current Ratio6.88 EPS Y/Y TTM81.94% Oper. Margin-52.24% RSI (14)37.14 Volatility7.80% 10.87%
Employees145 Debt/Eq6.88 Sales Y/Y TTM- Profit Margin-49.28% Recom1.25 Target Price8.50
Option/ShortYes / Yes LT Debt/Eq6.85 EPS Q/Q31.74% Payout- Rel Volume0.77 Prev Close0.84
Sales Surprise37.23% EPS Surprise11.76% Sales Q/Q- EarningsMar 13 AMC Avg Volume1.52M Price0.84
SMA20-12.57% SMA50-27.66% SMA200-14.60% Trades Volume212,797 Change-0.76%
Date Action Analyst Rating Change Price Target Change
Jun-25-24Initiated Oppenheimer Outperform $9
Apr-05-24Resumed Wedbush Outperform $4
Jul-27-23Downgrade UBS Buy → Neutral $8 → $1.25
Mar-07-23Downgrade Raymond James Outperform → Mkt Perform
Mar-01-23Initiated Guggenheim Neutral
Dec-07-22Downgrade SMBC Nikko Outperform → Neutral $3
Dec-07-22Downgrade JP Morgan Neutral → Underweight
Dec-07-22Downgrade Barclays Overweight → Equal Weight $18 → $2
Oct-20-22Initiated Goldman Buy $22
Sep-21-22Initiated JP Morgan Neutral $17
Apr-16-25 09:57AM
Apr-09-25 09:44AM
Apr-08-25 05:30PM
Mar-27-25 09:45AM
Mar-26-25 01:38PM
08:41AM Loading…
Mar-23-25 08:41AM
Mar-13-25 05:10PM
04:06PM
04:01PM
Mar-07-25 05:30PM
Feb-19-25 06:00AM
Feb-07-25 05:30PM
Feb-03-25 07:01AM
Jan-28-25 07:01AM
Jan-07-25 05:30PM
09:19AM Loading…
09:19AM
Dec-26-24 12:00PM
Nov-21-24 12:00PM
Nov-15-24 09:35AM
Nov-14-24 09:35AM
Nov-11-24 04:01PM
Nov-07-24 06:00PM
04:59PM
04:03PM
Oct-31-24 07:00AM
Oct-30-24 07:00AM
Oct-29-24 07:00AM
Oct-07-24 05:01PM
Sep-25-24 07:00AM
Sep-24-24 07:00AM
04:01PM Loading…
Aug-26-24 04:01PM
Aug-21-24 07:00AM
Aug-20-24 07:00AM
Aug-12-24 10:53PM
05:10PM
04:15PM
04:01PM
Jul-25-24 02:35AM
Jun-13-24 03:35PM
Jun-07-24 04:30PM
May-14-24 04:01PM
May-10-24 04:30PM
May-07-24 10:56PM
05:15PM
04:01PM
05:11AM
04:31AM
May-06-24 03:17PM
08:17AM
08:11AM
07:41AM
07:30AM
May-03-24 08:02AM
Mar-13-24 07:07AM
Mar-12-24 07:31AM
Mar-07-24 09:55AM
Mar-05-24 10:52PM
07:55AM
07:40AM
07:31AM
Feb-27-24 03:30AM
Jan-31-24 02:23PM
Jan-22-24 10:53AM
Jan-08-24 04:01PM
Dec-13-23 04:01PM
Dec-05-23 04:01PM
07:01AM
Nov-29-23 07:01AM
Nov-09-23 08:11AM
07:41AM
07:31AM
Oct-23-23 10:08AM
Oct-03-23 04:08PM
Sep-07-23 07:44AM
Aug-28-23 08:20AM
Aug-08-23 04:41PM
04:01PM
Jul-24-23 04:16PM
Jul-20-23 07:56AM
Jun-23-23 06:24AM
May-18-23 07:05AM
May-13-23 08:15AM
May-09-23 04:13PM
04:01PM
Apr-04-23 12:38PM
Mar-17-23 07:46AM
07:31AM
Mar-07-23 03:37PM
Mar-03-23 11:40AM
Feb-01-23 04:25PM
Jan-04-23 12:00PM
09:35AM
Dec-26-22 09:41AM
Dec-06-22 01:19PM
10:00AM
08:19AM
07:15AM
Nov-17-22 02:37PM
Nov-08-22 12:00PM
Nov-03-22 04:01PM
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Aranda RichardChief Medical OfficerJun 24 '24Sale0.661,9081,260196,891Jun 25 06:24 PM
Hasnain FaheemPresident & CEOJun 21 '24Buy0.67372,000250,2825,408,073Jun 24 05:52 PM
Giraudo BryanCOO/CFOJun 18 '24Buy0.59100,00059,110480,010Jun 20 08:21 PM
Smith Robert Paul JRChief Commercial OfficerJun 17 '24Buy0.6025,00015,05025,000Jun 20 08:20 PM